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ABSTRACT 
A series of spirocyclic compounds inspired by Eli Lilly’s phase 1 antidiabetic FFA1 receptor 
agonist LY2881835 was designed to include polar aromatic periphery groups and explore a 
possibility of building additional contacts with the target near the agonist binding site. The 
frontrunner compound in the series (9i) was shown to be a potent (EC50 = 260 nM) FFA1 agonist 
with excellent aqueous (PBS) solubility and good Caco-2 permeability. The observed structure-
activity relationships were rationalized by a docking study. The new series significantly expands 
the ligand landscape for the ongoing quest for new potent and more polar FFA1 agonists as 
fundamentally new class of therapeutic agents against type 2 diabetes mellitus. 
Keywords: Drug discovery; FFA1 agonists; antidiabetic agents; spirocyclic motifs; hydrophobic 
interactions; π−π stacking; reductive amination. 
1. Introduction 
De-orphaning of G-protein coupled receptor GPR40 in 2003 led to its being re-named as free fatty 
acid receptor 1 (FFA1) due to the demonstrated involvement of medium- to long-chain 
endogenous fatty acids in its activation [1]. Shortly thereafter, it was shown that the endogenous 
ligand binding to FFA1 regulates the secretion of insulin in pancreatic β-cells and is, therefore, 
linked to glucose homeostasis. Interestingly, the basal expression levels of FFA1 in normal state 
are low but do become upregulated in hyperglycemic states, which makes the receptor an ideal 
target for therapeutic intervention. Moreover, once the glucose levels are normalized, the level of 
FFA1 expression goes back to normal thereby preventing hypoglycemia, even if an agonist is still 
in circulation [2]. Taken together, these observations unquestionably validated FFA1 as a 
therapeutic target of great promise in delivering new treatment for type 2 diabetes mellitus (T2DM) 
which would be devoid of adverse reactions of the drugs currently in clinical use. The interest 
toward this target from the industry and academic research teams was clearly evidenced by the 
discovery of a number of synthetic agonists over the decade following FFA1 validation as an 
antidiabetic target [3]. Unfortunately, the field was adversely affected by the discontinuation of 
the phase III clinical trials of Takeda’s fasiglifam (TAK-875) in December 2013 due to 
idiosynchratic liver toxicity observed within an extended patient population, which caused a sharp 
drop in the amount of effort worldwide to bring new FFA1 agonists as drugs to the market [4]. At 
the time of preparing this manuscript, only two phase I clinical studies (Piramal’s compound 
P11187 of undisclosed structure and SHR0534 or fusiglifam from Hengrui) were underway [5]. 
This is rather unfortunate as in fact, the proof of principle for the new therapeutic approach was 
clearly obtained in the course of TAK-875 clinical research [6]. Considering the fact that FFA1 is 
mainly expressed in the pancreas and in the brain [7], the hepatotoxicity of TAK-875 is likely 
related to the specific molecular structure of this (rather lipophilic [8]) molecule and not to the 
action at the receptor. In fact, much of the research in the last 3 years (i. e. after the discontinuation 
of TAK-875) has been focused on the discovery and development of more polar, less lipophilic 
FFA1 agonists [9].  
Figure 1. Polar-appendage (1-2) and scaffold-hopping (3-4) approaches toward less lipophilic 
FFA1 agonists. 
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Aiming at more polar FFA1 agonists could be considered a ‘tug of war’ as lipophilicity is a known 
driver of ligand potency for the free fatty acid receptors [10]. A sensible approach toward this goal 
typically includes fine-tuning of either the polar appendage groups around the 3-phenypropionic 
acid pharmacophore (as in, for example, 1 [11] and 2 [12]) or replacing this core with more polar 
heterocyclic congeners, i.e. applying the scaffold-hopping approach exemplified by 3 [13] and 4 
[14] (Figure 1). Ideally, this is done in conjunction with attempts to create new specific interactions 
with the target that could compensate for the affinity loss due to the decreased lipophilicity [12, 
14].  
Figure 2. LY2881835 and the rational design of the earlier reported (6-8) and newly developed 
(9) FFA1 agonists.  
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Recently, we became intrigued by the structure of LY2881835 (5), Eli Lilly’s advanced FFA1 
agonist, which progressed through phase I clinical trials [3]. In addition to 3-phenylpropanoic acid 
pharmacophoric core, the compound contains a spirocyclic piperidine moiety with a basic amine 
nitrogen atom, which constitutes an unusual feature for the FFA1 agonist landscape [4]. More 
importantly, it extends the range of structural motifs that can be explored as periphery ‘decoration’ 
of potential FFA1 agonists in the ongoing quest for more polar compounds (as the tertiary amine 
nitrogen will most likely be protonated at physiological pH). In this context, we saw a great 
opportunity to incorporate a greater diversity of spirocyclic motifs (amenable by our recently 
reported Prins cyclization protocol [15]) into a new series of FFA1 agonists inspired by 
LY2881835. Spirocyclic moieties in general are considered privileged structures for GPCR ligand 
design due to their pronounced three-dimensional character, better complementarity to the protein 
target of interest and lower off-target effects [16].  This prompted us to develop a series of 
spirocyclic compounds which delivered lead structure 6 [17]. It has a potency of 55 nM which is 
in sharp contrast with inactive compound 7 where the 1-oxa-9-azaspiro[5.5]undecane periphery is 
unsubstituted. More recently, we have also demonstrated that incorporation of significantly more 
polar isosteres (as in compound 8, which is somewhat less potent with an EC50 900 nM) was also 
possible and is not detrimental to compound’s potency [18]. For compound 6, we demonstrated 
that the presence of the benzyl substituent (which is absent in inactive compound 7) provides more 
than just a lipophilicity-driven potency increase. The benzyl group appeared to define a specific 
orientation of the spirocyclic moiety in 6 (pointing toward the intracellular side of the receptor) 
reinforced by a network of favorable hydrophobic interactions with L542.51,  L1354.54 and V813.27 
as well as a π-stacking interaction with W1314.50 [17]. Such a consideration prompted us to 
investigate a series of compounds 9 in which a polar heteroaromatic moiety (as that in compound 
8) would be attached to the crucial 1-oxa-9-azaspiro[5.5]undecane system via a more flexible, 3-
atom linker to enable the compound to assume a more energetically favored conformation and 
accommodate the azine periphery within the nearby binding pocket (Figure 2). Herein, we disclose 
our recent results in this regard. 
2. Results and discussion 
2.1  Chemistry 
Retrosynthetically, the target compounds could be disconnected to building blocks 10 and 13, 
gram-scale synthesis of which had been reported earlier [17, 19] (Figure 3).  
 
Figure 3. Retrosynthetic analysis of spirocyclic FFA1 agonists 9 investigated in this work. 
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This synthetic strategy was realized as shown in Scheme 1. Key spirocyclic ketone 13 was 
prepared on multigram scale via the Prins cyclization of 1-benzyl-4-piperidone and homoallyl 
alcohol followed by the protecting group exchange [15] and secondary alcohol oxidation with PDC 
[17].  
Scheme 1. Synthesis of compound 9a-m investigated as FFA1 agonists in this work. 
N
O
O
O
OHArO
9a-m
NH
O
11a-m
N
O
12
HO
O
O
N
O
O
13
O
O
NO
Ph
OH
+
ref.15
Prins
 
cyclization
(Bn
 --> Boc)
alcohol
oxidation
ref.17
i
 - iii
41%
(3
 steps)
iv(v)
-vi
ArO
vii-viii
. nHCl . nTFA
 
Reagents and conditions: (i) EtOOCCH2P(O)(OEt)2, NaH, THF, 0 ºC  rt, 18 h; (ii) HCOONH4, 
10% Pd-C, EtOH, reflux, 12 h; (iii) LiAlH4, THF, rt, 2h; (iv) NaH, ArCl, DMF, 0 ºC  rt, 16 h 
(11b-l); (v) ArOH, DIAD, THF, 0 ºC  rt, 16 h (11a, 11m); (vi) TFA, CH2Cl2, 0 ºC, 6h; (vii) 10, 
Et3N, NaBH(OAc)3, CH2Cl2, 12 h, rt; (viii) 4M HCl, 1,4-dioxane, rt, 6h. 
The subsequent 2-hydroxyethyl side chain installation was achieved in three chemical operations 
including the Horner-Wadsworth-Emmons olefination reaction, double bond hydrogenation over 
a palladium catalyst using ammonium formate as a hydrogen source, and the LAH reduction of 
the ester functionality to the respective primary alcohol 12. A reasonable total chemical yield of 
41% was achieved for the three synthetic steps. Having installed the requisite 2-hydroxyethyl side 
chain, we proceeded to decorate it with a range of (hetero)aromatic groups. Most of these could 
be installed via a direct SNAr-type reaction of the alkoxide generated from 12 with heteroaromatics 
containing labile chloro-substituent.  Alternatively, respective hydroxyaromatic building block 
was coupled to 12 under the standard Mitsunobu conditions. Removal of the Boc protecting group 
with TFA furnished spirocyclic piperidine building blocks 11a-m which were alkylated with 
aldehyde 10 in reductive conditions (STAB) and, without purification, the resulting tert-butyl ester 
precursors were converted, using 4M HCl in 1.4-dioxane, to free carboxylic acids 9a-m, which 
were isolated as hydrochloride salts (Scheme 1). 
2.2 Biological activity 
Potential FFA1 agonists 9a-m synthesized as described above, were tested for their ability to 
activate FFA1 using calcium flux assay employing Chinese hamster ovary (CHO) cells engineered 
to stably express human FFA1. All compounds were tested in dose-response mode in order to 
calculate the respective EC50 values and determine % of maximum efficacy achieved for active 
compounds relative to commercially available reference FFA1 agonist GW9508 [20]. 
From the data obtained on activation of FFA1 receptor by compounds 9a-m (Table 1), it becomes 
evident that the idea of presenting polar aromatic periphery on an extended, three-atom linker 
resulted in low-micromolar potency for the majority of compounds (while the low potency of 9b 
is somewhat puzzling). Starting from the best compound in the azine-decorated series (8, EC50 = 
0.9 µM, vide supra) we reported earlier [18], the goal in present study was to optimize the same 
or similar polar azine (or other aromatic) periphery to be accommodated in the nearby binding 
pocket. The bioactivity data in Table 1 essentially reflect the gradual fine-tuning of the potency 
and the efficacy of compounds 9a-m until the best fit to the binding pocket manifests itself in 
compound 9i, which we regard as unquestionable frontrunner in this series. Compound 9i not only 
displays a pronounced restoration of the receptor affinity by the side chain present in it compared 
to its unsubstituted (inactive) counterpart 7, it also shows a significant improvement over its double 
homolog 8. Considering the fact that compounds 9h and 9i are mere positional isomers and, 
therefore, have an identical cLogP of 5.84 [21], the >4-fold difference in potency is likely 
attributable to the better accommodation of 9i by FFA1 (vide infra).  
 
 
 
 
Table 1. FFA1 agonists 9a-m studied in this work.  
N
O
O
O
OHArO
. nHCl
 
Compound Ar n FFA1 EC50 ± SD, µMa % efficacyb 
9a F *  1 2.06 ± 0.34 55.0 
9b 
N
F3C
*
 2 33.5 ± 1.54 79.2 
9c N *
 
2 2.36 ± 0.61 83.4 
9d 
N
N
*
 
2 1.14 ± 0.15 80.2 
9e 
N
N *
 
2 1.26 ± 0.47 78.4 
9f 
N
N
*
 
2 1.48 ± 0.28 83.5 
9g N
N  
2 1.21 ± 0.52 60.5 
9h 
N
*
 
2 1.11 ± 0.12 110.3 
9i N *
 
2 0.26 ± 0.07 100.3 
9j 
N
N
*
 
2 3.87 ± 1.01 54.5 
9k 
N
N
*
 
2 1.27 ± 0.44 104.9 
9l N *  2 6.10 ± 1.23 48.5 
9m N
*
 2 2.56 ± 0.33 61.7 
a Each value is an average of n = 4. 
b Relative to GW9508 [20] (5 µM). 
We further profiled lead compound 9i for selectivity against other free fatty acid receptors 
(FFA3/GPR41, FFA2/GPR43 and FFA4/GPR120). FFA2 and FFA3 bind short-chain fatty acids 
preferentially, while FFA1 and FFA4 have a higher affinity to medium-and long chain fatty acids 
[22-23]. Compound 9i showed no activation of any of these receptors (except for FFA1) at 
concentrations as high as 10 µM (Table 2).  
Table 2. Selectivity profile of compound 9i.a 
 EC50 (µM) 
Human FFA1/GPR40 0.26 
Human FFA3/GPR41 >10 
Human FFA2/GPR43 >10 
Human FFA4/GPR120 >10 
a Each value is an average of n = 4 in the presence of 0.1% BSA. 
We also obtained the preliminary ADME profile of 9i by determining its Caco-1 permeability, 
stability toward incubation with mouse liver microsomes (MLM) and solubility in aqueous 
phosphate buffer solution (Table 3).  Unsurprisingly, the polar substituted pyridine periphery led 
to significant aqueous solubility and the compound had a good Caco-2 permeability. The metabolic 
stability was somewhat low which was already reported for compounds with a similar molecular 
scaffold [17]. The rapid MLM clearance can indeed be attributed to the presence of two 
heteroatom-substituted benzylic positions in 9i and/or β-unsubstituted which is a known weak spot 
of FFA1 agonists, prone to metabolic oxidation [4]. 
Table 3. ADME profile of compound 9i. 
  
Aqueous solubility (PBS, pH 7.4)a (µM) 228 
Metabolic stability  
(mouse liver microsomes) 
T1/2, min 22.9 
CLint, µL/min/mg 72.8 
A-B permeability (Caco-2, cm∙s-1)b (∙10-6) 7.3 
a Each value is an average of n = 4, measured at c = 1 µM. 
b Each value is an average of n = 2, measured at c = 10 µM. 
 
2.3 Docking studies 
In order to rationalize the dramatic difference in potency between unsubstituted spirocyclic 
compound 7 reported earlier [17] and frontrunner compound 9i identified in this study, which 
differ only in the presence of 2-[(6-methylpyrid-2-yl)oxy]ethyl side chain in the 1-oxa-9-
azaspiro[5.5]undecane portion of 9i, we docked these compounds in the FFA1 binding site (Figure 
4). 
Figure 4. Docked poses of compounds 7 and 9i at FFA1. (A) Overlay of 7 (green) and 9i (orange) 
in the FFA1 binding site. (B) Hydrophobic interactions of the 2-[(6-methylpyrid-2-yl)oxy]ethyl 
side chain. Protein-ligand interactions are only visualized for compound 9i. Hydrogen bonds, π−π 
and hydrophobic interactions are in brown, blue and yellow dashed-lines, respectively. Each 
transmembrane helix is labeled in red roman numerals. Residues are labeled with their position 
followed by the Ballesteros and Weinstein numbering [24] in subscript. EL2 refers to the 
extracellular loop 2. 
 
Both compounds assume similar positions within the biding site (Figure 4A) forming critical 
hydrogen bonds with R1835.39, Y913.37 and Y2406.51 while the aromatic ring of the 
phenylpropanoic acid moiety is in close proximity to F883.34, F1424.61, W174EL2 and F873.33. The 
docking results clearly demonstrate that the  2-[(6-methylpyrid-2-yl)oxy]ethyl side chain of 9i is 
within the hydrophobic cavity encompassed by L542.51, V813.27,  W1314.50 and L1354.54 (Figure 
4B). Apparently, the attachment of the pyridyl moiety to the spirocyclic fragment of 7 with a 
flexible, three-atom linker allows an optimal positioning of the periphery heterocycle within this 
cavity with negligible strain on the ligand. It is clearly visible that the 6-methyl substituent is 
buried within the cavity, which facilitates the formation of the π−π stacking contact between the 
pyridine ring and W1314.50. The latter appears to be vital for stabilizing the bound conformation 
of the ligand and its strength depends on the substituents in the aromatic rings involved in the 
interaction [25]. This observation could, for instance, help rationalize the significantly decreased 
potency of compound 9b (EC50 = 33.5 µM), which is the only one in the series that has a strongly 
electron-withdrawing substituent in the azine ring. 
 
 
3. Conclusions 
We have successfully explored the possibility of decorating the 1-oxa-9-azaspiro[5.5]undecane 
portion of inactive compound 7 (reported earlier as inspired by LY2881835) with polar 
(hetero)aromatic heterocycles attached via a flexible 3-atom linker to enable the optimal 
accommodation of these residues within the hydrophobic pocket identified earlier near the binding 
site of FFA1 agonists. One of the resulting compounds (9i) displayed a high potency and efficacy 
as FFA1 agonist and demonstrated excellent aqueous solubility, Caco-2 permeability and 
somewhat rapid metabolism in the presence of human liver microsomes. The compound clearly 
provides a strong proof-of-principle for the design approach taken toward new antidiabetic agents 
acting via FFA1 activation that includes the use of polar periphery residues. These findings 
significantly expand the FFA1 agonist chemistry space for the ongoing quest for new, more polar 
agents that would have a lesser chance of displaying idiosyncratic hepatotoxicity. 
4. Experimental protocols 
All reactions were conducted in oven-dried glassware in atmosphere of nitrogen. Melting points 
were measured with a Buchi В-520 melting point apparatus and were not corrected. Analytical 
thin-layer chromatography was carried out on Silufol UV-254 silica gel plates using appropriate 
mixtures of ethyl acetate and hexane. Compounds were visualized with short-wavelength UV light. 
1H NMR and 13C NMR spectra were recorded on Bruker MSL-300 spectrometers in DMSO-D6-
d6 using TMS as an internal standard. Mass spectra were recorded using Shimadzu LCMS-2020 
system with electron-spray (ESI) ionization. All and reagents and solvents were obtained from 
commercial sources and used without purification. 
All mass-spectroscopic measurements required for determination of ADME properties were 
performed using Shimadzu VP HPLC system including vacuum degasser, gradient pumps, reverse 
phase HPLC column, column oven and autosampler. The HPLC system was coupled with tandem 
mass spectrometer API 3000 (PE Sciex). The TurboIonSpray ion source was used in both positive 
and negative ion modes. Acquisition and analysis of the data were performed using Analyst 1.5.2 
software (PE Sciex). 
4.1 Synthesis 
4.1.1 tert-Butyl 4-(2-hydroxyethyl)-1-oxa-90-azaspiro[5.5]undecane-9-carboxylate (12).  
To a 0 ºC, vigorously stirred suspension of NaH (6.54 g, 163 mmol, 60% dispersion in mineral 
oil) in THF (300 mL) thriethylphosphonoacetate (45 g, 200 mmol) was added dropwise under 
argon. The stirring continued at that temperature for 1 h, whereupon a solution of 13 (40 g, 149 
mmol), prepared as described earlier [17], in THF (100 mL) was added. The reaction mixture was 
allowed to reach r. t. and was stirred at that temperature for 18 h. The reaction mixture was poured 
into water (500 mL) and the aqueous phase was extracted with ethyl acetate (3 x 200 mL). The 
combined organic extracts wer washed with 3% aqueous citric acid, 5% aqueous NaHCO3, brine, 
dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was fractionated on 
silica gel using 05% ethyl acetate in hexanes as eluent. The fractions containing the olefination 
product (according to LC MS analysis) were pooled and concentrated to dryness (yielding 32.7 g 
of the material). The residue (10.9 g) was dissolved in EtOH (200 mL), HCOONH4 (2.8 g, 0.44 
mmol) and 10% Pd on carbon (300 mg) were added and the resulting mixture was heated at reflux 
for 12 h. The mixture was cooled to r. t. and filtered through a plug of Celite (subsequently washing 
the latter with EtOH). The combined filtrate and washings were concentrated to dryness. The 
residue was partitioned between water (150 mL) and ethyl acetate (150 mL). The organic layer 
was separated and the aqueous layer was additionally extracted with ethyl acetate (2 x 150 mL). 
The combined organic extracts were washed with 3% aqueous citric acid, 5% aqueous NaHCO3 
and brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo.  The residue was 
dissolved in dry THF (200 mL) and to this solution, LiAlH4 (1.1 g, 29.3 mmol) was added in small 
portions on vigorous stirring. The stirring continued at room temperature for 2 h whereupon water 
(1.1 mL), 15% aqueous NaOH (1.1 mL) and water (3.3 mL) were sequentially added. The residue 
formed was filtered off, washed with THF (2 x 50 mL) and the combined filtrate and washings 
were concentrated in vacuo to provide the analytically pure title compound. 
Amorphous solid, yield  18,266 mg (41% over 3 steps); 1H NMR (300 MHz, CDCl3) δ 3.77 – 3.63 
(m, 5H), 3.56 (td, J = 12.3, 2.2 Hz, 1H), 3.23 – 3.12 (m, 1H), 3.06 – 2.94 (m, 1H), 2.26 (s, 1H), 
2.19 – 2.10 (m, 1H), 1.94 – 1.78 (m, 1H), 1.66 – 1.52 (m, 2H), 1.51 – 1.45 (m, 3H), 1.43 (s, 9H), 
1.32 – 0.99 (m, 4H); 13C NMR (75 MHz, CDCl) δ 155.0, 79.3, 70.4, 60.7, 59.8, 42.9, 39.9, 39.8, 
39.8, 39.2, 32.7, 29.2, 28.5, 26.7; MS m/z 300.4 (M+H+). 
4.1.2 General procedure 1 (GP1): preparation of 1-oxa-9-azaspiro[5.5]undecanes 11b-l 
To 0 ºC suspension of NaH (60% suspension in mineral oil, 220 mg, 5.6 mmol) in dry DMF (100 
mL) a solution of 13 (1.0 g, 3.3 mmol) in dry DMF (20 mL) was added. The resulting mixture was 
stirred at 0 ºC for 30 min and then treated with a solution of the respective 2-chloroazine (5.0 
mmol) in dry DMF (10 mL). The mixture was allowed to warm up to r. t. and stirred at that 
temperature for 16 h. It was poured into water (200 mL) and the resulting slurry was extracted 
with ethyl acetate (3 x 200 mL). The combined organic extracts were washed with 5% aqueous 
citric acid, 5% aqueous NaHCO3, brine and dried over anhydrous Na2SO4. The solid drying agent 
was filtered off and the filtrate was concentrated in vacuo. The residue was dissolved in CH2Cl2 
(10 mL), the solution was cooled to 0 ºC and TFA (3 mL) was added. The mixture thus obtained 
was stirred at 0 ºC for 6 h and then concentrated in vacuo to dryness to provide, after crystallization 
from isopropyl alcohol, the target compounds as ditrifluoroacetate salts. 
4.1.3  4-(2-{[5-(Trifluoromethyl)pyridin-2-yl]oxy}ethyl)-1-oxa-9-azaspiro[5.5]undecane 
ditrifluoroacetate (11b) 
Viscous oil, yield 67%;  1H NMR (300 MHz, DMSO-d6) δ 8.56 – 8.53 (m, 1H), 8.33 (s, 1H), 8.03 
(dd, J1 = 2.61 Hz, J2 = 8.80 Hz, 1H), 6.97 (d, J = 8.74 Hz, 1H), 4.37 (t, J = 6.65 Hz, 2H), 3.68 – 
3.62 (m, 1H), 3.52 – 3.44 (m, 1H), 3.11 – 2.99 (m, 3H), 2.89 – 2.78 (m, 1H), 2.36 – 2.28 (m, 1H), 
1.93 – 1.80 (m, 1H), 1.72 – 1.52 (m, 6H), 1.46 – 1.35 (m, 1H), 1.19 – 0.97 (m, 2H); 13C NMR (75 
MHz, DMSO-d6) δ 165.7, 144.9 (q, J = 4.5 Hz), 136.4 (q, J = 3.1 Hz), 124.2 (q, J = 271.1 Hz), 
118.7 (q, J = 32.5 Hz), 111.4, 68.2, 63.9, 60.1, 41.8, 35.4, 32.0, 26.5, 25.6; MS m/z 345.5 (M+H+). 
4.1.4        4-[2-(Quinolin-2-yloxy)ethyl]-1-oxa-9-azaspiro[5.5]undecane ditrifluoroacetate (11с) 
Viscous oil, yield 24%;  1H NMR (300 MHz, DMSO-d6) δ 8.53 (s, 1H), 8.22 (d, J = 8.86 Hz, 1H), 
7.87 (d, J = 7.93 Hz, 1H), 7.75 (d, J = 8.29 Hz, 1H), 7.70 – 7.61 (m, 1H), 7.46 – 7.39 (m, 1H), 
6.99 (d, J = 8.84 Hz, 1H), 4.46 (t, J = 6.54 Hz, 2H), 3.71 – 3.63 (m, 1H), 3.56 – 3.42 (m, 1H), 3.14 
– 2.77 (m, 4H), 2.39 – 2.30 (m, 1H), 2.00 – 1.84 (m, 1H), 1.76 – 1.36 (m, 7H), 1.24 – 1.01 (m, 
2H); 13C NMR (75 MHz, DMSO-d6) δ 161.6, 145.9, 139.3, 129.8, 127.8, 126.6, 124.8, 124.1, 
113.0, 68.1, 63.0, 60.1, 41.9, 35.6, 35.4, 32.1, 28.4, 26.6, 25.6; MS m/z 327.4 (M+H+). 
4.1.5    4-{2-[(3,6-Dimethylpyrazin-2-yl)oxy]ethyl}-1-oxa-9-azaspiro[5.5]undecane 
ditrifluoroacetate (11d) 
Viscous oil, yield 45%;  1H NMR (300 MHz, DMSO-d6) δ 8.55 (s, 1H), 7.90 (s, 1H), 4.33 (t, J = 
6.41 Hz, 2H), 3.73 – 3.63 (m, 1H), 3.56 – 3.44 (m, 1H), 3.13 – 2.78 (m, 4H), 2.36 – 2.29 (m, 7H), 
1.96 – 1.81 (m, 1H), 1.72 – 1.55 (m, 6H), 1.47 – 1.35 (m, 1H), 1.21 – 1.00 (m, 2H); 13C NMR (75 
MHz, DMSO-d6) δ 157.1, 147.5, 140.1, 134.0, 68.2, 63.2, 60.2, 41.8, 35.4, 32.2, 26.7, 25.5, 20.3, 
18.4; MS m/z 306.3 (M+H+). 
4.1.6 4-[2-(6,7-Dihydro-5H-cyclopenta[d]pyrimidin-4-yloxy)ethyl]-1-oxa-9-
azaspiro[5.5]undecane ditrifluoroacetate (11e) 
Viscous oil, yield 45%;  1H NMR (300 MHz, DMSO-d6) δ 8.73 (s, 1H), 8.46 (d, J = 46.70 Hz, 
2H), 4.48 (t, J = 6.46 Hz, 2H), 3.67 (dd, J = 11.75, 4.34 Hz, 1H), 3.49 (t, J = 11.53 Hz, 1H), 3.09 
– 2.85 (m, 6H), 2.80 (t, J = 7.44 Hz, 2H), 2.33 (d, J = 14.23 Hz, 1H), 2.15 – 2.02 (m, 2H), 1.84 (d, 
J = 3.34 Hz, 1H), 1.71 – 1.11 (m, 9H); 13C NMR (75 MHz, DMSO-d6) δ 171.8, 166.0, 155.1, 
120.7, 68.1, 64.5, 60.1, 41.7, 35.4, 35.2, 32.8, 32.1, 26.6, 26.3, 25.5, 21.3; MS m/z 318.3 (M+H+). 
4.1.7 4-[2-(6,7-Dihydro-5H-cyclopenta[d]pyrimidin-4-yloxy)ethyl]-1-oxa-9-
azaspiro[5.5]undecane ditrifluoroacetate (11f) 
Viscous oil, yield 24%;  1H NMR (300 MHz, DMSO-d6) δ 8.47 (d, J = 49.34 Hz, 2H), 8.28 (s, 
1H), 8.20 – 8.18 (m, 2H), 4.34 (t, J = 6.59 Hz, 2H), 3.67 (dd, J = 11.69, 4.52 Hz, 1H), 3.49 (t, J = 
11.49 Hz, 1H), 3.12 – 2.77 (m, 4H), 2.33 (d, J = 14.60 Hz, 1H), 1.86 (d, J = 3.65 Hz, 1H), 1.69 – 
1.35 (m, 7H), 1.32 – 0.97 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 159.8, 140.8, 136.7, 135.37, 
68.1, 63.4, 60.1, 41.8, 35.4, 35.3, 32.0, 26.5, 25.6; MS m/z 278.5 (M+H+). 
4.1.8 4-{2-[(2-Cyclopropyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)oxy]ethyl}-1-oxa-9-
azaspiro[5.5]undecane ditrifluoroacetate (11g) 
Viscous oil, yield 40%;  1H NMR (300 MHz, DMSO-d6) δ 8.42 (s, 1H), 4.48 (t, J = 6.58 Hz, 2H), 
3.72 – 3.63 (m, 1H), 3.54 – 3.44 (m, 1H), 3.11 – 2.97 (m, 5H), 2.90 – 2.81 (m, 1H), 2.75 (t, J = 
7.55 Hz, 2H), 2.37 – 2.29 (m, 1H), 2.27 – 2.18 (m, 1H), 2.16 – 2.05 (m, 2H), 1.90 – 1.77 (m, 1H), 
1.71 – 1.52 (m, 6H), 1.47 – 1.36 (m, 1H), 1.25 – 1.01 (m, 6H); 13C NMR (75 MHz, DMSO-d6) δ 
168.7, 168.0, 166.6, 118.5, 68.1, 65.0, 60.0, 41.8, 35.4, 35.1, 31.9, 31.8, 26.5, 26.0, 25.5, 21.5, 
15.6, 11.6; MS m/z 358.2 (M+H+). 
4.1.9   4-{2-[(4-Methylpyridin-2-yl)oxy]ethyl}-1-oxa-9-azaspiro[5.5]undecane ditrifluoroacetate 
(11h) 
Viscous oil, yield 33%;  1H NMR (300 MHz, DMSO-d6) δ 8,03 (d, J = 5.35 Hz, 1H), 6.86 (d, J = 
6.12 Hz, 1H), 6.73 (s, 1H), 4.29 (t, J = 6.59 Hz, 2H), 3.71 – 3.62 (m, 1H), 3.56 – 3.43 (m, 1H), 
3.13 – 2.98 (m, 3H), 2.92 – 2.79 (m, 1H), 2.39 – 2.27 (m, 4H), 1.92 – 1.78 (m, 1H), 1.72 – 1.52 
(m, 6H), 1.47 – 1.35 (m, 1H), 1.23 – 0.99 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 163.0, 151.6, 
145.2, 118.5, 110.6, 68.1, 63.5, 60.1, 41.8, 35.6, 35.4, 32.1, 26.5, 25.6, 20.5; MS m/z 291.4 
(M+H+). 
4.1.10 4-{2-[(6-Methylpyridin-2-yl)oxy]ethyl}-1-oxa-9-azaspiro[5.5]undecane  ditrifluoroacetate 
(11i) 
Viscous oil, yield 40%;  1H NMR (300 MHz, DMSO-d6) δ 7.67 – 7.60 (m, 1H), 6.85 (d, J = 7.27 
Hz, 1H), 6.65 (d, J = 8.28 Hz, 1H), 4.28 (t, J = 6.59 Hz, 2H), 3.71 – 3.64 (m, 1H), 3.54 – 3.44 (m, 
1H), 3.08 – 2.82 (m, 4H), 2.38 (s, 3H), 2.36 – 2.29 (m, 1H), 1.92 – 1.80 (m, 1H), 1.71 – 1.55 (m, 
6H), 1.48 – 1.34 (m, 1H), 1.15 – 0.99 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 162.5, 155.2, 
140.2, 116.0, 107.3, 68.1, 63.1, 60.1, 41.9, 35.6, 35.4, 32.1, 26.5, 25.6, 23.3; MS m/z 291.2 
(M+H+). 
4.1.11 4-[2-(Pyrimidin-2-yloxy)ethyl]-1-oxa-9-azaspiro[5.5]undecane ditrifluoroacetate (11j) 
Viscous oil, yield 58%;  1H NMR (300 MHz, DMSO-d6) δ 8.59 (s, 1H), 8.57 (s, 1H), 7.11 (t, J = 
4.75 Hz, 1H), 4.34 (t, J = 6.50 Hz, 2H), 3.72 – 3.62 (m, 1H), 3.56 – 3.43 (m, 1H), 3.13 – 2.99 (m, 
3H), 2.91 – 2.79 (m, 1H), 2.38 – 2.30 (m, 1H), 1.94 – 1.78 (m, 1H), 1.72 – 1.53 (m, 6H), 1.48 – 
1.36 (m, 1H), 1.22 – 0.98 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 164.7, 159.6, 115.4, 68.1, 
64.3, 60.1, 41.8, 35.4, 32.0, 26.5, 25.6; MS m/z 278.0 (M+H+). 
4.1.12 4-{2-[(3-Methylpyrazin-2-yl)oxy]ethyl}-1-oxa-9-azaspiro[5.5]undecane ditrifluoroacetate  
(11k) 
Viscous oil, yield 46%;  1H NMR (300 MHz, DMSO-d6) δ 8.44 (dd, J = 55.56, 2.37 Hz, 2H), 8.08 
– 7.98 (m, 2H), 4.35 (t, J = 6.57 Hz, 2H), 3.67 (dd, J = 11.73, 4.47 Hz, 1H), 3.49 (dd, J = 19.25, 
8.64 Hz, 1H), 3.14 – 2.75 (m, 4H), 2.40 – 2.29 (m, 4H), 1.95 – 1.78 (m, 1H), 1.75 – 1.32 (m, 7H), 
1.23 – 0.99 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 157.9, 143.9, 138.3, 135.4, 68.1, 63.4, 60.1, 
41.8, 35.4, 35.3, 32.1, 26.7, 25.5, 19.0; MS m/z 292.5 (M+H+). 
4.1.13 4-[2-(Pyridin-4-yloxy)ethyl]-1-oxa-9-azaspiro[5.5]undecane  ditrifluoroacetate (11l) 
Viscous oil, yield 58%;  1H NMR (300 MHz, DMSO-d6) 8.77 (d, J = 7.32 Hz, 2H), 7.56 (d, J = 
7.36 Hz, 2H), 4.38 (t, J = 6.59 Hz, 2H), 3.73 – 3.64 (m, 1H), 3.56 – 3.45 (m, 1H), 3.14 – 2.97 (m, 
3H), 2.93 – 2.78 (m, 1H), 2.37 – 2.29 (m, 1H), 1.95 – 1.81 (m, 1H), 1.74 – 1.54 (m, 6H), 1.49 – 
1.36 (m, 1H), 1.24 – 1.01 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 170.6, 143.4, 112.98, 68.1, 
60.0, 41.5, 35.3, 34.9, 31.8, 26.3, 25.5; MS m/z 276.8 (M+H+). 
4.1.14 General procedure 2 (GP2): preparation of 1-oxa-9-azaspiro[5.5]undecanes 11a and 11m 
 To a 0 ºC solution of 13 (1.0 g, 3.3 mmol), hydroxyaromatic coupling partner (4.3 mmol) and 
triphenylphosphine (1.29 g, 4.9 mmol) in dry THF (100 mL) a solution of DIAD (1.0 g, 4.9 mmol) 
in dry THF (10 mL) was added dropwise. The resulting mixture was stirred for 16 h at r.t., poured 
into water (100 mL) and the resulting slurry extracted with ethyl acetate (3 x 50 mL). The 
combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
The residue was dissolved in 7:3 diethyl ether-hexane mixture (30 mL) and the solution cooled to 
5 ºC. The precipitate of triphenylphosphine oxide was filtered off and the filtrate concentrated in 
vacuo. The residue was fractionated on a short column of silica gel using 0  5% ethyl acetate in 
hexane as eluent. The fractions containing the Mitsunobu reaction product (according to LC MS 
analysis) were pooled and the solvent was evaporated. The residue was dissolved in CH2Cl2 (10 
mL), the solution was cooled to 0 ºC and TFA (3 mL) was added. The mixture thus obtained was 
stirred at 0 ºC for 6 h and then concentrated in vacuo to dryness to provide, after crystallization 
from isopropyl alcohol, the target compounds as mono- (11a) or ditrifluoroacetate (11m) salts. 
4.1.14 4-[2-(4-Fluorophenoxy)ethyl]-1-oxa-9-azaspiro[5.5]undecane hydrochloride (11a) 
The trifluoroacetate salt obtained according to GP2, was transformed into hydrochloride salt by 
trituration with 4M solution of HCl in 1,4-dioxane (to avoid absorption of moisture by the 
hygroscopic TFA salt).  
White crystals, mp = 183-186 ºC, yield 64%; 1H NMR (300 MHz, DMSO-d6) δ 8.95 (s, 2H), 7.13 
– 7.06 (m, 2H), 6.96 – 6.90 (m, 2H), 3.96 (t, J = 6.41 Hz, 2H), 3.69 – 3.62 (m, 1H), 3.52 – 3.44 
(m, 1H), 3.07 – 2.74 (m, 4H), 2.33 – 2.29 (m, 1H), 1.87 – 1.44 (m, 8H), 1.19 – 0.97 (m, 2H); 13C 
NMR (75 MHz, DMSO-d6) δ 156.4 (d, J = 235.6 Hz), 154.9 (d, J = 1.73 Hz), 115.8 (d, J = 16.6 
Hz), 115.6 (d, J = 1.2 Hz), 68.2, 65.5, 60.0, 41.8, 35.7, 35.2, 32.0, 26.4, 25.4; MS m/z 294.5 
(M+H+). 
4.1.15 4-[2-(Pyridin-3-yloxy)ethyl]-1-oxa-9-azaspiro[5.5]undecane ditrifluoroacetate (11m) 
Viscous oil, yield 48%. 1H NMR (300 MHz, DMSO-d6) δ 8.66 – 8.63 (m, 1H), 8.51– 8.46 (m, 
1H), 8.09 – 8.05 (m, 1H), 7.92 – 7.85 (m, 1H), 4.23 (t, J = 6.5 Hz, 2H), 3.73 – 3.65 (m, 1H), 3.55 
– 3.45 (m, 1H), 3.13 – 2.99 (m, 3H), 2.93 – 2.80 (m, 1H), 2.38 – 2.30 (m, 1H), 1.97 – 1.83 (m, 
1H), 1.74 – 1.55 (m, 6H), 1.49 – 1.37 (m, 1H), 1.23 – 1.01 (m, 2H); 13C NMR (75 MHz, DMSO-
d6) δ 156.6, 135.7, 131.1, 129.8, 127.2, 68.1, 67.0, 60.1, 41.7, 35.4, 35.3, 31.9, 26.4, 25.6; MS m/z 
277.4 (M+H+). 
4.1.16 General procedure 3 (GP3): preparation of compounds 9a-m 
A solution of the respective spirocyclic piperidine salt 11a-m (0.46 mmol) in CH2Cl2 (5 mL) was 
treated with triethylamine (n x 0.46 mmol, where n = number of salt parts per molecule) followed 
by a solution of 10 (0.44 mmol) in CH2Cl2 (5 mL). After a brief stirring (15 min), sodium 
triacetoxyborohydride (STAB, 1.32 mmol) was added and the stirring continued for 12 h at r. t. 
The reaction was poured into 10% aqueous NaHCO3 (20 mL). Organic phase was separated and 
the aqueous phase was extracted with CH2Cl2 (2 x 10 mL). The combined organic extracts were 
washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue 
was fractionated on silica gel using 01% MeOH in CH2Cl2. The fractions containing the 
reductive amination product (according to LC MS analysis) were pooled and concentrated in 
vacuo. The residue was dissolved in CH2Cl2 (3 mL) and treated with TFA (1 mL). The mixture 
was stirred at r. t. for 18 h and concentrated in vacuo. 2M HCl in ether (3 mL) was added to the 
residue and the later was triturated (with occasional sonication) until a crystalline hydrochloride 
salt formed. The latter was separated by filtration, washed with ether and dried in vacuo to provide 
analytically pure compounds 9a-m. 
4.1.17 3-(4-{[4-({4-[2-(4-Fluorophenoxy)ethyl]-1-oxa-9-azaspiro[5.5]undec-9-
yl}methyl)benzyl]oxy}phenyl)propanoic acid hydrochloride (9a) 
White crystalline solid, mp = 198-201 ºC, yield 83 mg (0.132 mmol, 30%); 1H NMR (300 MHz, 
DMSO-d6) δ 11.11 (s, 1H), 7.67 (d, J = 7.91 Hz, 2H), 7.49 (d, J = 7.91 Hz, 2H), 7.13 (d, J = 8.56 
Hz, 2H), 7.08 (t, J = 8.74 Hz, 2H), 6.95 – 6.90 (m, 4H), 5.09 (s, 2H), 4.39 – 4.23 (m, 2H), 3.97 (t, 
J = 6.50 Hz, 2H), 3.70 – 3.60 (m, 1H), 3.53 – 3.45 (m, 1H), 3.13 – 2.85 (m, 4H), 2.75 (t, J = 7.55 
Hz, 2H), 2.48 (t, J = 7.55 Hz, 2H), 2,45 – 4.41 (m, 1H), 2.05 –1.47 (m, 8H), 1.17 – 1.02 (m, 2H); 
13C NMR (75 MHz, DMSO-d6) δ 173.7, 156.5, 156.3 (d, J = 235.4 Hz), 154.9 (d, J = 1.9 Hz), 
138.5, 133.1, 131.5, 129.3, 129.2, 127.7, 115.7 (d, J = 22.4 Hz), 115.6, 114.5, 68.6, 67.8, 65.5, 
60.0, 58.3, 46.9, 46.9, 41.8, 35.7, 35.5, 32.0, 29.4, 26.6, 25.5; HRMS (ESI), m/z calcd for 
C34H40FNO5 [M+H+] 562.2969, found 562.2963. 
4.1.18  3-{4-[(4-{[4-(2-{[5-(Trifluoromethyl)pyridin-2-yl]oxy}ethyl)-1-oxa-9-
azaspiro[5.5]undec-9-yl]methyl}benzyl)oxy]phenyl}propanoic acid dihydrochloride (9b) 
White crystalline solid, mp = 198-201 ºC, yield 40 mg (0.059 mmol, 13.4%); 1H NMR (300 MHz, 
DMSO-d6) δ 10.60 (s, 1H), 8.56 (s, 1H), 8.04 (dd, J1 = 2.31 Hz, J2 = 8.87 Hz, 1H), 7.50 (dd, J1 = 
7.86 Hz, J2 = 37.80 Hz, 4H), 7.13 (d, J = 8.54 Hz, 2H), 7.04 – 6.95 (m, 1H), 6.92 (d, J = 8.51 Hz, 
2H), 5.09 (s, 2H), 4.38 – 4.27 (m, 4H), 3.69 – 3.61 (m, 1H), 3.58 – 3.41 (m, 1H), 3.15 – 2.83 (m, 
4H), 2.74 (t, J = 7.55 Hz, 2H), 2.48 (t, J = 7.55 Hz, 2H), 2.44 – 2.40 (m, 1H), 2.02 – 1.78 (m, 2H), 
1.69 – 1.40 (m, 4H), 1.23 – 0.97 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 173.8, 165.6, 156.5, 
145.0 (q, J = 4.3 Hz), 138.5, 136.4 (q, J = 2.9 Hz), 133.1, 131.5, 129.3, 129.27, 127.8, 124.1 (q, J 
= 271.1 Hz), 118.6 (q, J = 32.4 Hz), 114.5, 111.4, 68.6, 67.8, 63.9, 60.0, 58.4, 47.0, 46.9, 41.8, 
35.5, 35.5, 32.0, 30.7, 29.5, 26.6, 25.6; HRMS (ESI), m/z calcd for C34H39F3N2O5 [M+H+] 
613.2889, found 613.2883. 
4.1.19 3-(4-{[4-({4-[2-(Quinolin-2-yloxy)ethyl]-1-oxa-9-azaspiro[5.5]undec-9-
yl}methyl)benzyl]oxy}phenyl)propanoic acid dihydrochloride (9c) 
White crystalline solid, mp = 118-124 ºC, yield 136 mg (0.204 mmol, 44.3%); 1H NMR (300 MHz, 
DMSO-d6) δ 10.88 (s, 1H), 8.24 (d, J = 8.9 Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H), 7.77 (d, J = 8.1 Hz, 
1H), 7.64 (d, J = 8.0 Hz, 3H), 7.49 (d, J = 7.9 Hz, 2H), 7.42 (t, J = 7.4 Hz, 1H), 7.13 (d, J = 8.4 
Hz, 2H), 7.00 (d, J = 8.8 Hz, 1H), 6.91 (d, J = 8.4 Hz, 2H), 5.08 (s, 2H), 4.45 (t, J = 6.4 Hz, 2H), 
4.37 – 4.25 (m, 2H), 3.70 – 3.62 (m, 1H), 3.49 (t, J = 11.9 Hz, 1H), 3.14 – 2.82 (m, 2H), 2.74 (t, J 
= 7.5 Hz, 2H), 2.46 (t, J = 7.7 Hz, 2H), 2.46 – 2.41 (m, 1H), 2.05 – 1.85 (m, 2H), 1.73 – 1.50 (m, 
6H), 1.25 – 1.01 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 173.8, 161.6, 156.6, 145.5, 139.7, 
138.5, 133.1, 131.6, 129.9, 129.3, 129.3, 127.8, 126.4, 124.7, 124.2, 117.0, 114.6, 112.9, 68.7, 
67.9, 66.4, 63.3, 60.1, 58.4, 47.0, 46.9, 42.0, 35.6, 32.1, 30.7, 29.5, 26.8, 25.6; HRMS (ESI), m/z 
calcd for C37H42N2O5 [M+H+] 595.3172, found 595.3166. 
4.1.20  3-[4-({4-[(4-{2-[(3,6-Dimethylpyrazin-2-yl)oxy]ethyl}-1-oxa-9-azaspiro[5.5]undec-9-
yl)methyl]benzyl}oxy)phenyl]propanoic acid dihydrochloride (9d) 
White crystalline solid, mp = 137-144 ºC, yield 81 mg (0.126 mmol, 27.4%); 1H NMR (300 MHz, 
DMSO-d6) δ 11.14 (s, 1H), 7.92 (s, 1H), 7.66 (d, J = 7.41 Hz, 2H), 7.48 (d, J = 7.59 Hz, 2H), 7.13 
(d, J = 8.19 Hz, 2H), 6.91 (d, J = 8.14 Hz, 2H), 5.08 (s, 2H), 4.36 – 4.23 (m, 4H), 3.69 – 3.62 (m, 
1H), 3.55 – 3.43 (m, 1H), 3.12 – 2.81 (m, 4H), 2.74 (t, J = 6.95 Hz, 2H), 2.48 (t, J = 6.95 Hz, 2H), 
2.38 – 2.32 (m, 7H), 2.05 – 1.98 (m, 1H), 1.92 – 1.79 (m, 1H), 1.72 – 1.49 (m, 6H), 1.21 – 1.03 
(m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 173.9, 157.3, 156.6, 148.1, 139.8, 138.5, 133.2, 133.0, 
131.7, 129.4, 129.3, 127.9, 114.6, 68.7, 67.9, 63.4, 60.1, 58.4, 47.0, 47.0, 35.6, 35.5, 35.3, 32.2, 
30.8, 29.5, 26.8, 25.5, 20.5, 18.1; HRMS (ESI), m/z calcd for C34H43N3O5 [M+H+] 574.3281, found 
574.3275. 
4.1.21  3-(4-{[4-({4-[2-(6,7-Dihydro-5H-cyclopenta[d]pyrimidin-4-yloxy)ethyl]-1-oxa-9-
azaspiro[5.5]undec-9-yl}methyl)benzyl]oxy}phenyl)propanoic acid dihydrochloride (9e) 
Amorphous solid, yield 44 mg (0.067 mmol, 14.6%); 1H NMR (300 MHz, DMSO-d6) δ 10.87 (s, 
1H), 8.73 (s, 1H), 7.64 (d, J = 7.9 Hz, 2H), 7.49 (d, J = 7.9 Hz, 2H), 7.13 (d, J = 8.5 Hz, 2H), 6.91 
(d, J = 8.5 Hz, 2H), 5.08 (s, 2H), 4.47 (t, J = 6.6 Hz, 2H), 4.40 – 4.24 (m, 2H), 3.65 (dd, J = 11.3, 
3.8 Hz, 1H), 3.57 – 3.42 (m, 1H), 3.15 – 2.70 (m, 10H), 2.46 (t, J = 7.2 Hz, 2H), 2.45 – 2.38 (m, 
1H), 2.13 – 2.02 (m, 2H), 2.01 – 1.52 (m, 8H), 1.27 – 1.01 (m, 2H); 13C NMR (75 MHz, DMSO-
d6) δ 173.8, 171.7, 165.9, 156.5, 154.9, 138.5, 133.1, 131.6, 129.3, 129.2, 127.8, 120.7, 114.5, 
68.6, 67.8, 64.4, 60.0, 58.3, 47.0, 46.9, 41.8, 35.5, 35.2, 32.7, 32.0, 30.7, 29.5, 26.7, 26.2, 25.5, 
21.3; HRMS (ESI), m/z calcd for C35H43N3O5 [M+H+] 586.3281, found 586.3294. 
4.1.22 3-(4-{[4-({4-[2-(Pyrazin-2-yloxy)ethyl]-1-oxa-9-azaspiro[5.5]undec-9-
yl}methyl)benzyl]oxy}phenyl)propanoic acid dihydrochloride (9f) 
White crystalline solid, mp = 196-199 ºC, yield 92 mg (0.149 mmol, 32.4%); 1H NMR (300 MHz, 
DMSO-d6) δ 11.00 (s, 1H), 8.78 (t, J = 6.0 Hz, 1H), 7.81 (d, J = 6.3 Hz, 2H), 7.66 (d, J = 8.2 Hz, 
2H), 7.50 (d, J = 8.2 Hz, 2H), 7.14 (d, J = 8.7 Hz, 2H), 6.92 (d, J = 8.7 Hz, 2H), 5.09 (s, 2H), 4.51 
(dd, J = 5.6, 2.4 Hz, 2H), 4.42 – 4.25 (m, 2H), 3.66 (d, J = 7.6 Hz, 1H), 3.50 (t, J = 11.3 Hz, 1H), 
3.13 – 2.81 (m, 4H), 2.75 (t, J = 7.5 Hz, 2H), 2.47 (t, J = 7.4 Hz, 2H), 2.47 – 2.42 (m, 1H), 2.19 – 
1.92 (m, 4H), 1.74 – 1.38 (m, 4H), 1.21 – 1.01 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 174.2, 
172.0, 160.0, 157.0, 142.5, 138.9, 133.6, 132.0, 129.8, 129.7, 128.2, 125.0, 115.0, 69.1, 68.3, 60.4, 
58.7, 47.4, 47.4, 42.8, 42.1, 36.0, 35.8, 32.3, 29.9, 27.8, 25.9; HRMS (ESI), m/z calcd for 
C32H39N3O5 [M+H+] 546.2968, found 546.2986. 
4.1.23 3-[4-({4-[(4-{2-[(2-Cyclopropyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)oxy]ethyl}-
1-oxa-9-azaspiro[5.5]undec-9-yl)methyl]benzyl}oxy)phenyl]propanoic acid dihydrochloride (9g) 
Amorphous solid, yield 108 mg (0.155 mmol, 33.7%); 1H NMR (300 MHz, DMSO-d6) δ 11.10 (s, 
1H), 7.58 (dd, J1 = 8.06 Hz, J2 = 52.18 Hz, 4H), 7.03 (dd, J1 = 8.56 Hz, J2 = 66.37 Hz, 4H), 5.08 
(s, 2H), 4.48 (t, J = 6.58 Hz, 2H), 4.40 – 4.24 (m, 2H), 3.70 – 3.62 (m, 1H), 3.53 – 3.43 (m, 1H), 
3.15 – 2.99 (m, 5H), 2.92 – 2.83 (m, 1H), 2.79 – 2.70 (m, 4H), 2.48 (t, J = 7.55 Hz, 2H), 2.44 – 
2.34 (m, 2H), 2.19 – 2.09 (m, 2H), 2.06 – 1.95 (m, 1H), 1.89 – 1.76 (m, 1H), 1.72 – 1.43 (m, 6H), 
1.31 – 1.02 (m, 6H); 13C NMR (75 MHz, DMSO-d6) δ 173.7, 167.6, 167.5, 167.4, 166.8, 156.5, 
138.5, 133.1, 131.5, 129.3, 129.2, 127.7, 119.1, 114.5, 68.6, 67.8, 65.4, 60.0, 58.3, 46.9, 46.8, 41.8, 
35.5, 35.4, 34.9, 31.9, 31.4, 29.5, 26.6, 25.9, 25.4, 21.6, 15.0, 12.0; HRMS (ESI), m/z calcd for 
C38H47N3O5 [M+H+] 626.3594, found 626.3574. 
4.1.24 3-[4-({4-[(4-{2-[(4-Methylpyridin-2-yl)oxy]ethyl}-1-oxa-9-azaspiro[5.5]undec-9-
yl)methyl]benzyl}oxy)phenyl]propanoic acid dihydrochloride (9h) 
White crystalline solid, mp = 30-32 ºC, yield 112 mg (0.177 mmol, 38.5%); 1H NMR (300 MHz, 
DMSO-d6) δ 11.15 (s, 1H), 8.07 (d, J = 5.49 Hz, 1H), 7.58 (dd, J1 = 8.10 Hz, J2 = 54.84 Hz, 4H), 
7.14 (d, J = 8.69 Hz, 2H), 6.99 – 6.87 (m, 4H), 5.09 (s, 2H), 4.41 – 4.23 (m, 4H), 3.69 – 3.62 (m, 
1H), 3.56 – 3.43 (m, 1H), 3.14 – 2.99 (m, 3H), 2.95 – 2.83 (m, 1H), 2.75 (t, J = 7.55 Hz, 2H), 2.48 
(t, J = 7.55 Hz, 2H), 2.45 – 2.39 (m, 1H), 2.34 (s, 3H), 2.09 – 1.95 (m, 1H), 1.90 – 1.78 (m, 1H), 
1.72 – 1.47 (m, 6H), 1.25 – 1.00 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 173.7, 162.1, 156.5, 
153.8, 143.6, 138.4, 133.1, 131.6, 129.3, 129.2, 127.7, 118.7, 114.5, 110.7, 68.6, 67.8, 64.6, 60.0, 
58.3, 46.9, 46.8, 41.8, 35.5, 35.4, 32.0, 29.5, 26.6, 25.5, 20.8; HRMS (ESI), m/z calcd for 
C34H42N2O5 [M+H+] 559.3172, found 559.3166. 
4.1.25    3-[4-({4-[(4-{2-[(6-Methylpyridin-2-yl)oxy]ethyl}-1-oxa-9-azaspiro[5.5]undec-9-
yl)methyl]benzyl}oxy)phenyl]propanoic acid dihydrochloride  (9i) 
White crystalline solid, mp = 147-150 ºC, yield 127 mg (0.202 mmol, 43.9%); 1H NMR (300 MHz, 
DMSO-d6) δ 11.04 (s, 1H), 7.76 – 7.64 (m, 3H), 7.52 – 7.47 (m, 2H), 7.14 (d, J = 8.65 Hz, 2H), 
6.95 – 6.88 (m, 3H), 6.78 – 6.72 (m, 1H), 5.09 (s, 2H), 4.41 – 4.24 (m, 4H), 3.70 – 3.63 (m, 1H), 
3.55 – 3.43 (m, 1H), 3.13 – 2.83 (m, 4H), 2.75 (t, J = 7.59 Hz, 2H), 2.48 (t, J = 7.59 Hz, 2H), 2.46 
– 2.42 (m, 1H), 2.41 (s, 3H), 2.07 – 1.95 (m, 1H), 1.91 – 1.79 (m, 1H), 1.74 – 1.45 (m, 6H), 1.25 
– 1.03 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 173.8, 162.0, 156.5, 154.6, 138.5, 133.1, 131.6, 
129.3, 129.2, 127.8, 116.4, 114.5, 107.4, 68.6, 67.8, 64.0, 60.0, 58.3, 47.0, 46.9, 41.9, 35.5, 35.5, 
32.0, 29.5, 26.5, 26.6, 25.5, 22.6; HRMS (ESI), m/z calcd for C34H42N2O5 [M+H+] 559.3172, found 
559.3164. 
4.1.26 3-(4-{[4-({4-[2-(Pyrimidin-2-yloxy)ethyl]-1-oxa-9-azaspiro[5.5]undec-9-
yl}methyl)benzyl]oxy}phenyl)propanoic acid dihydrochloride  (9j) 
Amorphous solid, yield 112 mg (0.182 mmol, 39.6%); 1H NMR (300 MHz, DMSO-d6) δ 11.07 (s, 
1H), 8.31 – 8.26 (m, 1H), 8.22 – 8.17 (m, 2H), 7.66 (d, J = 7.31 Hz, 2H), 7.48 (d, J = 7.51 Hz, 
2H), 7.14 (d, J = 8.33 Hz, 2H), 6.92 (d, J = 8.42 Hz, 2H), 5.09 (s, 2H), 4.39 – 4.23 (m, 4H), 3.70 
– 3.61 (m, 1H), 3.57 – 3.42 (m, 1H), 3.16 – 3.00 (m, 3H), 2.95 – 2.82 (m, 1H), 2.75 (t, J = 7.55 
Hz, 2H), 2.48 (t, J = 7.55 Hz, 2H), 2.45 – 2.40 (m, 1H), 2.08 – 1.95 (m, 1H), 1.91 – 1.77 (m, 1H), 
1.73 – 1.47 (m, 6H), 1.26 – 1.01 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 173.7, 159.7, 156.5, 
140.8, 138.4, 136.6, 135.2, 133.1, 131.5, 129.2, 127.7, 114.5, 68.6, 67.8, 63.9, 60.0, 58.3, 46.9, 
46.8, 41.8, 35.5, 35.4, 35.3, 31.9, 29.4, 26.6, 25.5; HRMS (ESI), m/z calcd for C32H39N3O5 [M+H+] 
546.2968, found 546.2962. 
4.1.27  3-[4-({4-[(4-{2-[(3-Methylpyrazin-2-yl)oxy]ethyl}-1-oxa-9-azaspiro[5.5]undec-9-
yl)methyl]benzyl}oxy)phenyl]propanoic acid dihydrochloride  (9k) 
Amorphous solid, yield 80 mg (0.127 mmol, 27.6%); 1H NMR (300 MHz, DMSO-d6) δ 10.92 (s, 
1H), 8.08 – 8.00 (m, 2H), 7.65 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 7.13 (d, J = 8.5 Hz, 
2H), 6.91 (d, J = 8.5 Hz, 2H), 5.08 (s, 2H), 4.39 – 4.25 (m, 4H), 3.66 (dd, J = 11.7, 4.8 Hz, 1H), 
3.49 (dd, J = 13.0, 10.7 Hz, 1H), 3.15 – 2.80 (m, 4H), 2.74 (t, J = 7.5 Hz, 2H), 2.46 (t, J = 7.5 Hz, 
2H), 2.44 – 2.36 (m, 4H), 2.06 – 1.77 (m, 2H), 1.72 – 1.48 (m, 6H), 1.21 – 1.00 (m, 2H); 13C NMR 
(75 MHz, DMSO-d6) δ 173.7, 157.9, 156.5, 143.7, 138.5, 138.37, 135.23, 133.14, 131.54, 129.29, 
129.19, 127.73, 114.59, 68.69, 67.80, 63.41, 60.09, 58.4, 47.0, 46.9, 41.8, 35.5, 35.2, 32.1, 30.6, 
29.4, 26.8, 25.5, 18.8; HRMS (ESI), m/z calcd for C33H41N3O5 [M+H+] 560.3124, found 560.3116. 
4.1.28 3-(4-{[4-({4-[2-(Pyridin-4-yloxy)ethyl]-1-oxa-9-azaspiro[5.5]undec-9-
yl}methyl)benzyl]oxy}phenyl)propanoic acid dihydrochloride (9l) 
White crystalline solid, mp = 33-36 ºC, yield 144 mg (0.234 mmol, 50.9%); 1H NMR (300 MHz, 
DMSO-d6) δ 11.20 (s, 1H), 8.74 (d, J = 6.86 Hz, 2H), 7.67 (d, J = 7.96 Hz, 2H), 7.55 (d, J = 6.77 
Hz, 2H), 7.48 (d, J = 8.05 Hz, 2H), 7.13 (d, J = 8.60 Hz, 2H), 6.92 (d, J = 8.64 Hz, 2H), 5.09 (s, 
2H), 4.43 – 4.25 (m, 4H), 3.70 – 3.63 (m, 1H), 3.54 – 3.45 (m, 1H), 3.13 – 2.84 (m, 4H), 2.75 (t, 
J = 7.55 Hz, 2H), 2.48 (t, J = 7.55 Hz, 2H), 2.45 – 2.40 (m, 1H), 2.08 – 1.96 (m, 1H), 1.93 – 1.80 
(m, 1H), 1.76 – 1.50 (m, 6H), 1.27 – 1.05 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ 175.4, 162.3, 
158.3, 152.2, 140.9, 139.9, 132.7, 130.0, 128.9, 127.9, 115.7, 106.1, 76.5, 70.3, 66.4, 62.7, 60.3, 
51.3, 38.1, 36.3, 35.9, 35.4, 33.9, 33.7, 32.6, 30.1; HRMS (ESI), m/z calcd for C33H40N2O5 [M+H+] 
545.3015, found 545.3010. 
4.1.29 3-(4-{[4-({4-[2-(Pyridin-3-yloxy)ethyl]-1-oxa-9-azaspiro[5.5]undec-9-
yl}methyl)benzyl]oxy}phenyl)propanoic acid dihydrochloride (9m) 
White crystalline solid, mp = 168-171 ºC, yield 127 mg (0.206 mmol, 44.8%); 1H NMR (300 MHz, 
DMSO-d6) δ 11.11 (s, 1H), 8.73 – 8.64 (m, 1H), 8.49 – 8.46 (m, 1H), 8.13 – 8.08 (m, 1H), 7.94 – 
7.86 (m, 1H), 7.58 (dd, J = 7.96, 52.28 Hz, 4H), 7.02 (dd, J = 8.01, 66.37 Hz, 4H), 5.08 (s, 2H), 
4.41 – 4.21 (m, 4H), 3.70 – 3.63 (m, 1H), 3.54 – 3.45 (m, 1H), 3.15 – 3.03 (m, 3H), 2.93 – 2.84 
(m, 1H), 2.75 (t, J = 7.55 Hz, 2H), 2.48 (t, J = 7.55 Hz, 2H), 2.44 – 2.40 (m, 1H), 2.09 – 1.95 (m, 
1H), 1.91 – 1.80 (m, 1H), 1.74 – 1.50 (m, 6H), 1.24 – 1.04 (m, 2H); 13C NMR (75 MHz, DMSO-
d6) δ 173.7, 156.6, 156.5, 138.5, 135.1, 133.1, 131.6, 131.1, 130.3, 130.3, 129.3, 129.2, 127.9, 
127.7, 127.3, 114.6, 68.6, 67.8, 67.1, 60.0, 58.3, 46.9, 46.8, 41.6, 35.5, 35.4, 35.2, 31.9, 29.5, 26.5, 
25.5; HRMS (ESI), m/z calcd for C33H40N2O5 [M+H+] 545.3015, found 545.3006. 
4.2 Biological and ADME assays 
4.2.1 Determination of agonistic activity of compounds against FFA1 (GPR40), FFA3 (GPR41), 
FFA2 (GPR43) and FFA4 (GPR120) receptors 
CHO cells stably expressing human GPR40 (stable CHO-GPR40 line created at Enamine Ltd.) 
were seeded (12,500 cells/well) into 384-well black-wall, clear-bottom microtiter plates 24 h prior 
to assay. Cells were loaded for 1 h with fluorescent calcium dye (Fluo-8 Calcium Assay kit, Abcam, 
ab112129) and tested using fluorometric imaging plate reader (FLIPR Tetra® High Throughput 
Cellular Screening System, Molecular Devices Corp.). Maximum change in fluorescence over 
base line was used to determine agonist response. A potent and selective agonist for FFA1 
(GPR40) GW9508 (Selleckchem, S8014) was tested with the test compounds as a positive control. 
Concentration response curve data were fitted using Molecular Devices ScreenWorks® System 
Control Software (Molecular Devices). For specificity screening for possible GPR41, GPR43 and 
GPR120 agonism, CHO cell lines stably expressing the respective receptors (purchased from The 
European Collection of Cell Cultures, ECACC) were used. 
4.2.2 Determination of aqueous solubility (PBS, pH 7.4) 
The test compound (9i) and the reference compound (Ondansetron hydrochloride, Sigma-Aldrich, 
O3639), were assessed for kinetic solubility in phosphate-buffered saline: 138 mM NaCl, 2.7 mM 
KCl, 10 mM K-phosphate, pH 7.4 with 2% final DMSO. Solubility measurements were done using 
filter microplate technique with UV-quantification for all compounds. Using a 40 mM stock 
solution of each compound in 100% DMSO, dilutions were prepared to a theoretical concentration 
of 800 μM in duplicates in phosphate-buffered saline pH 7.4 with 2% final dimethyl sulfoxide 
(DMSO) and then transferred to a 96-well, deep well polypropylene collection plate. In parallel, 
compound dilutions in 50% methanol/PBS mixes were prepared at concentrations of 0 μM (blank), 
200 μM and 400 μM in duplicates to generate calibration curves. The experimental compound 
dilutions in PBS were further allowed to equilibrate at 25°C on a thermostatic orbital shaker for 
two hours and then filtered through HTS solubility filter plates (EMD Millipore, MSSLBPC)  
using a vacuum manifold. The filtrates adjusted for the calibration sample non-aqueous solvent 
content by 2-fold dilution with methanol, and the calibrating solutions were analyzed using 
SpectraMax UV-Vis microplate reader (200-550 nm absorbance scan, 5 nm step increment). The 
concentrations of compounds in PBS filtrate were determined using a dedicated Microsoft Excel 
calculation script. Proper absorbance wavelengths for calculations were selected for each 
compound manually based on absorbance maxima (absolute absorbance unit values for the 
minimum and maximum concentration points within 0 - 3 OD range). Each of the final datasets 
was additionally visually evaluated by the operator and goodness of fit (R2) was calculated for 
each calibration curve. The reference compound was included in every separate solubility 
experiment to control proper assay performance.  
4.2.3 Assessment of metabolic stability in mouse liver microsomes 
The metabolic stability of compound 9i as well as the reference compounds (Imipramine, 
Propranolol) was determined in liver microsomes at five time points over 40 minutes using HPLC-
MS. Mouse hepatic microsomes were isolated from pooled (50), perfused livers of BALB/c male 
mice according to the standard protocol [26]. The batch of microsomes was tested for quality 
control using a commercial comparator preparation (Sigma-Aldrich M9441) and verapamil and 
propranolol as reference compounds. Microsomal incubations were carried out in 96-well plates 
in 5 aliquots of 40 μL each (one for each time point). Liver microsomal incubation medium 
contained potassium phosphate buffer (100 mM, pH 7.4), MgCl2 (3.3 mM), NADPН (3 mM), 
glucose-6-phosphate (5.3 mM), glucose-6-phosphate dehydrogenase (0.67 units/ml) with 0.42 mg 
of liver microsomal protein per mL. In addition, control incubations were performed replacing the 
NADPH-regenerating system with 100 mM phosphate buffer pH 7.4. Test compounds (2 μM, final 
solvent concentration 1.6 %) were incubated at 37°C under vortexing at 100 rpm. Five time points 
over 40 minutes had been analyzed. The reactions were stopped by adding 12 volumes of 90% 
acetonitrile-water to 40 μL incubation aliquots, followed by plasma protein precipitation by 
centrifuging at 5500 rpm for 3 minutes. Incubations were performed in duplicates. Supernatants 
were analyzed using the HPLC system coupled with tandem mass spectrometer. The elimination 
constant (kel), half-life (T1/2) and intrinsic clearance (Clint) were determined in plot of ln(AUC) 
versus time, using linear regression analysis: 
kel = - slope 
T1/2 = 0.693/kel 
CLint = (0.693/ T1/2) x (µl incubation/mg microsomes) 
4.2.4 Caco-2 permeability assay. 
Caco-2 cells (human colorectal adenocarcinoma line, ATCC, Cat. HTB-37) were cultivated in 
DMEM medium supplemented with 10% FBS, 1% non-essential amino acids solution and 0,1% 
penicillin-streptomycin in humidified atmosphere at 37oC in 5% CO2 to 70 – 80% confluence and 
then were seeded at 1x105 cells/well on 24-well semipermeable insert plates (Millicell Multiwell 
PCF 0.4 µm or similar). The medium was changed every two days. After 10 days of cell growth 
the integrity of differentiated Caco-2 monolayers was verified by transepithelial electrical 
resistance (TEER) measurements using Milicell-ERS Voltohmmeter (Millipore EMD). Caco-2 
cell monolayers were considered acceptable for transport studies if the final values of TEER were 
greater than 1000 ohm/cm2. For the permeability studies, 24-well insert plate was removed from 
its feeder plate and placed in a new sterile 24-well receiver plate. The cell layer was washed twice 
with Phosphate-Buffered Saline. Aliquots (300 µL) of the test compound solution (in duplicates, 
at 10 µM, in HBSS with 5,6 mM glucose buffered with 10 mM HEPES, pH 7.4) were added into 
the apical compartments of the trans-well insert and 1000 µL of the same buffer was added to the 
basolateral compartments. The plates were then incubated for 2h at 37 ºC. High, low and 
intermediate permeability controls (Atenolol, Propranolol, Quinidine) were run with every 
experimental batch to verify assay validity. The concentrations of the compounds tested in the A-
B permeability assay were determined using HPLC-MS method. The LC system comprised 
Shimadzu liquid chromatograph equipped with isocratic pumps (Shimadzu LC-10ADvp), 
autosampler (Shimadzu SIL-HTc), switching valve (FCV-14AH) and degasser (Shimadzu DGU-
14A). Mass spectrometric analysis was performed using API 3000 (triple-quadrupole) instrument 
from PE Sciex with electro-spray (ESI) interface. The data acquisition and system control were 
performed using Analyst 1.5.2 software from PE Sciex. 
The formula for calculating Papp (expressed in 10-6 cm/sec) was as follows: 
Papp = (VA/((Area) x (Time)) x  ([drug]acc/[drug]init,d), where 
VA - volume of transport buffer in acceptor well, 
Area - surface area of the insert (equals to effective growth area of the insert), 
Time - time of the assay, 
[drug]acc - concentration of test compound in the acceptor well, 
[drug]init,d - initial concentration of test compound in the donor well. 
 
4.3 Docking studies 
The 3D coordinates for GPR40 co-crystalized with TAK-875 was obtained from the Protein Data 
Bank (PDB ID: 4PHU) [27] and used for subsequent docking procedures. Protein preparation, 
refinement and docking was performed within Schrodinger’s Maestro, version 2016-1 [28].  To 
prepare FFA1 receptor for docking, hydrogens and missing atoms were added, alternate residue 
positions were defined and the hydrogen bonding network was further optimized by re-orientating 
hydroxyls, amides and imidazole rings (of histidine residues) using the Protein Preparation Wizard 
[29]. For selecting an appropriate docking protocol, TAK-875 was re-docked onto FFA1 and 
compared to the crystal structure orientation, RMSD < 2.5 Å.  The remaining parameters and steps 
for receptor grid generation, ligand preparation and docking protocols were similar to the 
methodology of our previous studies [14b, 17]. Here we utilized the MacroModel [30], LigPrep 
[31] and GLIDE [32] modules of Schrödinger’s Maestro. To allow the comparison of residue 
positions within the GPCR family, the labels of residues are shown the Ballesteros Weinstein 
indexing system in subscript [24].  
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